Vanda appoints Dr. Tage Honoré to Board, expanding from 5 to 6 directors

Vanda Pharmaceuticals Inc.

Board expanded to six members, five independent; Dr. Honoré appointed as Class I director.
Initial equity grant $337,500 (50% options, 50% RSUs) + $50k annual retainer.
Annual equity award $225,000 after each annual meeting; change-of-control acceleration.
Dr. Honoré held exec roles at Novo Nordisk, Novartis, Purdue; discovered AMPA receptors.
No related party transactions; independent under Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tage Honoré

director

VNDA · Vanda Pharmaceuticals Inc.

Effective: 2023-03-15
Filed: March 17, 2023, 7:59 PM ET

On March 15, 2023, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from five to six members, effective immediately and appointed Tage Honoré, Ph.D., D.Sc., as a director of the Company to fill the vacancy created by the expansion.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Tage Honoré was appointed as director at Vanda Pharmaceuticals Inc..

Action: appointed
Role: director

Exact text from the filing

On March 15, 2023, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from five to six members, effective immediately and appointed Tage Honoré, Ph.D., D.Sc., as a director of the Company to fill the vacancy created by the expansion.

View on SEC.gov

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-008386

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.